Real-time enrollment status for this metastatic hormone-sensitive prostate cancer (mhspc) clinical trial
Current Status
Recruiting
Checked: October 15, 2026 at 6:33 PM UTC
| NCT Number | NCT07711002 |
| Recruiting Status | Recruiting |
| Condition | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) |
| Phase | PHASE3 |
| Target Enrollment | 1,330 participants |
| Active Locations | 42 sites in the US |
| Sponsor | AstraZeneca |
| Last Updated on CT.gov | October 15, 2026 (18 hours ago) |
As of October 15, 2026: Clinical trial NCT07711002 is currently recruiting participants. This phase3 study for metastatic hormone-sensitive prostate cancer (mhspc) is actively seeking new participants at 42 locations across the United States. The study is sponsored by AstraZeneca. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07711002 is actively recruiting participants as of October 15, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 42 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07711002 was last updated 18 hours ago (October 15, 2026). HelloStudys verifies this status automatically.